GHK CU.

GHK CU is a research compound in the copper & cosmetic peptides.

Copper-binding peptides studied in skin, wound, and collagen biology.

It draws interest for copper & cosmetic peptides.

D-tier evidence: human evidence is limited; most support is preclinical.

What it is

GHK-Cu is the copper(II) complex of GHK, a naturally occurring human tripeptide with the sequence glycyl-L-histidyl-L-lysine. GHK was first isolated from human plasma by Loren Pickart in the early 1970s and also occurs in saliva and urine; it binds copper ions with high affinity to form the violet-colored GHK-Cu complex. The free peptide sequence is embedded within the alpha-2 chain of type I collagen, and it is thought to be liberated during tissue injury, making it a candidate endogenous signal of tissue damage and repair. It is best known as a cosmetic ingredient and a widely studied "copper peptide."

How it works

GHK is a copper-coordinating molecule: the glycine amino terminus, the histidine imidazole, and a deprotonated peptide nitrogen form a square-planar Cu(II) chelate, a geometry confirmed by X-ray and solution-structure studies, allowing GHK to shuttle copper to and from cells and to modulate copper's redox chemistry. Beyond copper transport, GHK-Cu has been reported to stimulate fibroblast synthesis of collagen, elastin, glycosaminoglycans, and proteoglycans while modulating matrix metalloproteinases, consistent with a role in dermal remodeling. Bioinformatic analysis using the Broad Institute Connectivity Map found that GHK alters the expression of a large fraction of assayed human genes in cultured cells (upregulating some and suppressing others), including genes tied to antioxidant defense, anti-inflammatory signaling, DNA repair, and tissue regeneration. It has also shown antioxidant behavior in vitro, including blocking copper-dependent oxidation of low-density lipoprotein.

What the evidence shows

The strongest human evidence is cosmetic/dermatologic: small topical studies of GHK-Cu-containing creams have reported improvements in skin appearance, density, and wrinkles, but these are generally short, small, and often industry-adjacent rather than large randomized therapeutic trials. Much of the mechanistic case rests on in vitro and animal work — fibroblast cultures, rodent and rabbit wound-healing models, and rat nerve-regeneration experiments — plus gene-expression analyses (Pickart & Margolina, Int J Mol Sci 2018; Pickart et al., BioMed Res Int 2015). A notable bioinformatic finding is that GHK was computationally identified, via Connectivity Map screening of a human COPD lung gene signature, as a compound predicted to reverse that disease-associated expression pattern (Meiners & Eickelberg, Genome Medicine 2012) — but this was a transcriptomic prediction, not a clinical trial, and GHK was not administered to patients. There are no large controlled human trials supporting injected/systemic GHK-Cu for anti-aging, organ repair, or the regenerative claims often made online; that gap between mechanistic plausibility and proven clinical benefit is wide.

Safety considerations

In topical cosmetic use GHK-Cu has a long track record and is generally well tolerated, with the main reported issues being local irritation, redness, or contact sensitivity in some users. The safety of injected or systemic GHK-Cu in humans is not established by rigorous clinical study, and because the molecule carries copper, concerns about copper loading and pro-oxidant copper redox chemistry are biologically plausible and not well characterized for non-topical use. Purity, sterility, and actual copper content of research-grade or compounded products are unverified and vary by supplier. Overall, human safety data outside cosmetic topical contexts is thin, and unknowns dominate.

Regulatory status

GHK-Cu is not an FDA-approved drug; it is used as a cosmetic skincare ingredient (where cosmetic ingredients are not FDA pre-approved) and is otherwise sold for research/investigational purposes. It is not an approved therapeutic for wound healing, anti-aging, or any systemic indication, and it is not currently a WADA-prohibited substance.

1. [1]Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data — International Journal of Molecular Sciences, 2018, 19(7):1987; PMID 29986520
2. [2]GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration — BioMed Research International, 2015; PMID 26236730
3. [3]X-ray and solution structures of Cu(II) GHK and Cu(II) DAHK complexes: influence on their redox properties — Chemistry (A European Journal), 2011; PMID 21780203
4. [4]Next-generation personalized drug discovery: the tripeptide GHK hits center stage in chronic obstructive pulmonary disease — Genome Medicine, 2012; PMID 22999295

• Topical cosmetic use is common; systemic/injected use is research-only and less characterized.
• “Reverses aging” and systemic-benefit claims go well beyond the topical evidence.

Stack fit

Why not C: held back by human evidence, regulatory clarity.

Why not F: supported by preclinical depth.

What would move it up: Larger controlled human trials, clearer long-term safety, replicated findings, and regulatory progress.

What would move it down: Failed confirmatory trials, new safety signals, or evidence that popular claims don't translate.

• GHK CU is not FDA-approved for human use; it is discussed in a research context.
• It belongs to the Copper & cosmetic peptides class.
• Its principal mechanism is characterized in the literature.

• Whether observed effects reliably translate to humans at large.
• Long-term safety in healthy users, and full drug-interaction risk.
• Optimal studied parameters outside any approved indication.
• Claim-by-claim verdicts — these are authored against verified sources and shown when complete.
• Quality and purity of material from non-pharmaceutical sources.

1. What it is
2. The Copper-peptide signalling mechanism
3. The preclinical evidence lane
4. Why Early, and not higher or lower
5. Proven lane vs speculative lane
6. What people report
7. Regulatory status
8. What changed recently